Literature DB >> 19479263

Combination of BCG and interferon intravesical immunotherapy: an update.

Kenneth G Nepple1, Howard A Aubert, Matthew R Braasch, Michael A O'Donnell.   

Abstract

OBJECTIVE: To provide an update on the use of interferon (IFN) in the treatment of non-muscle invasive bladder cancer (NMIBC).
METHODS: A literature review of intravesical IFN was performed.
RESULTS: In vitro evidence suggested that IFN combined with BCG may have a synergistic effect on the immune response, and treatment regimens with IFN have used reduced BCG dosage in an attempt to reduce toxicity. IFN combined with BCG may salvage some patients, single-course BCG failures or late relapsers, while those that relapse quickly may be destined to failure. However, based on the results of a recently reported randomized trial, the addition of IFN may not improve efficacy in BCG naïve patients.
CONCLUSIONS: BCG plus IFN remains an alternative in selected patients with NMIBC who fail intravesical BCG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479263     DOI: 10.1007/s00345-009-0429-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  26 in total

1.  The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.

Authors:  Fadi N Joudi; Brian J Smith; Michael A O'Donnell; Badrinath R Konety
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

Review 2.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

3.  Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin.

Authors:  A Morales; P Ottenhof; L Emerson
Journal:  J Urol       Date:  1981-05       Impact factor: 7.450

4.  Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.

Authors:  Adrian P M van der Meijden; Richard J Sylvester; Wim Oosterlinck; Wolfgang Hoeltl; Aldo V Bono
Journal:  Eur Urol       Date:  2003-10       Impact factor: 20.096

5.  Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.

Authors:  J A Martínez-Piñeiro; N Flores; S Isorna; E Solsona; J L Sebastián; C Pertusa; L A Rioja; L Martínez-Piñeiro; R Vela; J E Camacho; J L Nogueira; I Pereira; L Resel; P Muntañola; F Galvis; N Chesa; J A De Torres; J Carballido; C Bernuy; S Arribas; R Madero
Journal:  BJU Int       Date:  2002-05       Impact factor: 5.588

Review 6.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

Review 7.  Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures.

Authors:  Fadi N Joudi; Michael A O'Donnell
Journal:  Curr Opin Urol       Date:  2004-09       Impact factor: 2.309

8.  Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

Authors:  Brian L Gallagher; Fadi N Joudi; José L Maymí; Michael A O'Donnell
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

9.  Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Authors:  N A Fanger; C R Maliszewski; K Schooley; T S Griffith
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

10.  Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.

Authors:  N Kayagaki; N Yamaguchi; M Nakayama; H Eto; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  9 in total

1.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 2.  New therapies for non-muscle-invasive bladder cancer.

Authors:  Edmund Chiong; Kesavan Esuvaranathan
Journal:  World J Urol       Date:  2009-09-18       Impact factor: 4.226

Review 3.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 4.  Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy.

Authors:  D R Yates; M Rouprêt
Journal:  World J Urol       Date:  2011-05-05       Impact factor: 4.226

Review 5.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

6.  Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion.

Authors:  John Wai-Man Yuen; Mayur-Danny I Gohel; Chi-Fai Ng
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-28       Impact factor: 2.629

7.  socs7, a target gene of microRNA-145, regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells.

Authors:  S Noguchi; N Yamada; M Kumazaki; Y Yasui; J Iwasaki; S Naito; Y Akao
Journal:  Cell Death Dis       Date:  2013-02-07       Impact factor: 8.469

8.  Immunotherapy for urothelial carcinoma: current status and perspectives.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

Review 9.  Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Authors:  Jeffrey J Tomaszewski; Marc C Smaldone
Journal:  Open Access J Urol       Date:  2010-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.